We are live on ! Find out more
HBIO icon

Harvard Bioscience

87 hedge funds and large institutions have $121M invested in Harvard Bioscience in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 38 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

39% more capital invested

Capital invested by funds: $87.3M → $121M (+$34.1M)

9% more funds holding

Funds holding: 8087 (+7)

0.11% more ownership

Funds ownership: 7.37%7.48% (+0.11%)

42% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 38

Holders
87
Holders Change
+7
Holders Change %
+8.75%
% of All Funds
1.88%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
22
Reduced
38
Closed
5
Calls
$2K
Puts
Net Calls
+$2K
Net Calls Change
+$2K
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Investments
51
Two Sigma Investments
New York
$214K -$122K -3,355 -40%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$210K -$979 -27 -0.6%
TA
53
Teachers Advisors
New York
$197K
MSL
54
Mackay Shields LLC
New York
$179K +$11.2K +310 +8%
SIM
55
Spark Investment Management
New York
$143K
Arrowstreet Capital
56
Arrowstreet Capital
Massachusetts
$136K -$29K -801 -20%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$117K +$1.2K +33 +1%
AIG
58
American International Group
New York
$100K -$2.72K -75 -3%
Two Sigma Advisers
59
Two Sigma Advisers
New York
$100K -$725 -20 -0.9%
KCM
60
Kennedy Capital Management
Missouri
$97K +$81.9K +2,260 New
Bank of Montreal
61
Bank of Montreal
Ontario, Canada
$96K -$1.89K -52 -2%
ZCM
62
Zebra Capital Management
Connecticut
$95K +$10.3K +285 +15%
FDCDDQ
63
Federation des caisses Desjardins du Quebec
Quebec, Canada
$69.6K
EGM
64
Engineers Gate Manager
New York
$69K -$1.74K -48 -3%
GC
65
Globeflex Capital
California
$68K
WPC
66
White Pine Capital
Minnesota
$67K
VOYA Investment Management
67
VOYA Investment Management
Georgia
$65K
Axa
68
Axa
France
$59K
Goldman Sachs
69
Goldman Sachs
New York
$58K +$49.1K +1,353 New
PPA
70
Parametric Portfolio Associates
Washington
$55K +$46.4K +1,280 New
Barclays
71
Barclays
United Kingdom
$48K +$36.6K +1,009 +807%
PP
72
PDT Partners
New York
$45K -$11.6K -320 -24%
Citigroup
73
Citigroup
New York
$41K +$2.46K +68 +8%
JP Morgan Chase
74
JP Morgan Chase
New York
$38K -$1.52K -42 -5%
Morgan Stanley
75
Morgan Stanley
New York
$33K -$284K -7,840 -91%

HBIO Hedge Fund Activity: Q1 2019 in Review

87 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2019, worth a combined $121M — up 39% from $87.3M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new HBIO positions and 5 closed out — a net gain of 7 holders — while 22 added to existing stakes and 38 trimmed.

The largest buyer was Bank of America, adding an estimated $1.48M. The largest seller was Algert Global, cutting an estimated $1.08M.

  • 87 institutional investors held Harvard Bioscience (HBIO) as of Q1 2019, up from 80 in Q4 2018.
  • Funds reported $121M of Harvard Bioscience stock for Q1 2019, up 39% quarter-over-quarter.
  • 12 funds opened new Harvard Bioscience positions in Q1 2019 and 5 closed out, a net change of +7 holders.
  • The largest Harvard Bioscience buyer in Q1 2019 was Bank of America, an estimated $1.48M added.
  • The largest Harvard Bioscience seller in Q1 2019 was Algert Global, an estimated $1.08M sold.

Based on aggregated 13F filings for Q1 2019.